androgen receptor degrader RO7656594

An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon oral administration, AR degrader RO7656594 targets, binds to and degrades AR, thereby preventing AR-mediated signaling and inhibiting the proliferation of AR-overexpressing tumor cells. AR, a hormone-regulated transcription factor, plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).